Clinical Trial Update: Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) [Phase 3]

View source ↗

Summary

Phase 3 trial JAVELIN OVARIAN PARP 100 evaluating avelumab with talazoparib in untreated advanced ovarian cancer was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Avelumab (avelumab)
• Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Ovarian Cancer | Phase 3 | Status: TERMINATED | Results posted: 2023-04-06